As part of the Population Sciences Branch (PSB), the Levy Lab conducts genetic and multidimensional omics research focused on cardiovascular disease (CVD) and its risk factors. Two important areas of the Levy Lab's intramural research are: 1) blood pressure (BP) genetics 2) multidimensional omics of BP and CVD The Levy Lab leverages the exceptional genotype and phenotype resources of the Framingham Heart Study (FHS) as well as NIH intramural resources including NHLBI's DNA Sequencing and Genomics Core Laboratory, CIT's Mathematical and Statistical Computing Laboratory, and NCBI's Computational Biology and Informational Engineering Branches. The Levy Lab was highly productive during the past four-year interval with over 100 publications. Goals for the PSB and Levy Lab: Goal 1: Identify genetic contributions to BP. Hypertension affects 80 million adults in the U.S. and it is a major contributor to multiple forms of CVD including coronary heart disease (CHD), stroke, and heart failure. Dr. Levy's research in hypertension focuses on cross-cutting studies of its genetic, transcriptomic, and epigenetic underpinnings. To advance research in the area of BP genetics, Dr. Levy leads or co-leads several large BP consortium working groups. BP projects summarized in this report include: new genome-wide association studies of common BP variants, studies of uncommon and rare BP variants from exome sequencing and Exome Chip genotyping, and sequencing the mitochondrial genome to find rare variants with large effects on BP. These complementary approaches have succeeded in identifying scores of novel variants and genes associated with BP. The results of Dr. Levy's research provide clues to novel genes and pathways involved in BP regulation and highlight potential therapeutic targets for the treatment of hypertension and the prevention of its sequelae. Goal 2: Apply multidimensional omics to identify biomarker signatures of BP and CVD. Under Dr. Levy's leadership, NHLBI initiated a high-risk, high-reward research program called the Systems Approach to Biomarker Research in Cardiovascular Disease Initiative (SABRe CVD) that applied multidimensional omics technologies at the population level to accelerate the discovery of biomarker signatures of CVD and its risk factors. Identifying novel CVD biomarkers has important implications for understanding disease biology and developing targeted prevention strategies in the preclinical phase of CVD when intervention is most likely to be effective. Discovering highly predictive biomarkers of CVD risk could represent a breakthrough for risk stratification if this approach improves upon current risk assessment methods. The SABRe CVD Initiative introduced four omics resources Project 1: discovery proteomics, metabolomics, and lipidomics Project 2: multiplexed immunoassays of high value candidate proteins Project 3: genome-wide transcriptomic profiling Project 4: microRNA profiling An additional omics resource recently introduced by the Levy Lab using DIR resources is genome-wide characterization of DNA methylation. Most recently PSB initiated three new research programs in FY2018-19: 1. Measure Extracellular RNA in Framingham Participants (Collaboration with USUHS) 2. Conduct state of the art RNA Sequencing in over 1200 Framingham Participants (Part of NHLBI's TOPMed Program) 3. The Role of Mitochondria in Cardiometabolic Disease (Collaboration with Boston University and TOPMed) Extracellular RNAs (exRNAs) impact a wide range of biological processes and function to transfer genetic information between cells. In doing so, exRNAs affect cell-to-cell communications. Recent studies indicate that exRNAs are associated with a variety of diseases. Emerging data from elderly participants in the Framingham Heart Study (FHS) demonstrate that circulating levels of exRNA are correlated with several key traits including age, sex, and body mass index. Much more work is needed to determine the extent to which exRNAs are associated with a variety of clinically relevant traits across the age spectrum. The primary aim RNA Sequencing will be the identification of expression quantitative trait loci (eQTLs) genome wide via the alignment of whole genome DNA sequencing and RNA sequencing. This approach will also permit the assessment of allele specific expression genome wide and alternative splicing QTLs (sQTLs) genome wide. A genome-wide resource of eQTLs and sQTLs would be a major contribution to the literature and would aid in the interpretation of genome-wide association studies Pilot data from our laboratories implicate mitochondrial DNA (mtDNA) in the pathogenesis of cardiometabolic disease (CMD), but the underlying mechanisms are not clear. We are developing a program to study mitochondrial variation across study cohorts and provide additional statistical power to allow us to define with great precision what is driving mtDNA associations, thus enabling a targeted exploration of the underlying mechanistic links between mtDNA and cardiometabolic risk. A key issue will be separating cause from effect, but by capitalizing on our expertise in cardiometabolic disease and mitochondrial genetics and biology, and exploiting our extensive cellular and model systems, we are uniquely placed to resolve this important issue. In the past year, PSB has made several recent advances in analysis of multidimensional omics data including: discovery and targeted proteomics of CHD, transcriptomic and systems biology analyses of BP and CHD, DNA methylation signatures of BP, and integrative genomic approaches to identify mechanisms underlying CVD traits and promising therapeutic targets for treatment and prevention. Our SH2B3/Beta-2 Microglobulin biomarker project, just recently published, could have wide ranging implications for updated BP therapeutic pathways. We continue to seek and expand these advances and add more complimentary data sets to delve deeper and deeper into genetic modification of subclinical atherosclerotic cardiovascular diseases and CMD.
Showing the most recent 10 out of 242 publications
